U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07948577) titled 'Henagliflozin on Myocardial Fibrosis in Obese Patients' on Nov. 01.
Brief Summary: This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Myocardial Fibrosis
Obesity
Intervention:
DRUG: Henagliflozin 10 mg
Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dos...